CELYAD ONCOLOGY financials
CELYAD ONCOLOGY
549300ORR0M8XF56OI64 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €186.0K | €102.0K |
| Cost of sales | €12.0K | €69.0K |
| Gross profit | €173.0K | €33.0K |
| Other income | €440.0K | €2.3M |
| Operating profit (EBIT) | -€5.9M | -€8.5M |
| Finance costs | €119.0K | €84.0K |
| Profit before tax | -€5.8M | -€8.5M |
| Income tax expense | €0 | -€63.0K |
| Profit for the year | -€5.8M | -€8.4M |
| Total comprehensive income | -€5.8M | -€8.4M |
| Per share | ||
| Basic EPS | €-0.14 | €-0.34 |
| Diluted EPS | €-0.14 | €-0.34 |
| Free cash flow / share | €-0.14 | €-0.65 |
| Cash flow statement | ||
| Net cash from operating activities | -€5.7M | -€15.2M |
| Net cash from investing activities | -€103.0K | €407.0K |
| Purchase of PP&E (capex) | €0 | €899.0K |
| Purchase of intangibles | €118.0K | €35.0K |
| Net cash from financing activities | €3.0M | €9.4M |
| Repayments of borrowings | €0 | €320.0K |
| Lease liability payments | €167.0K | €145.0K |
| Balance sheet | ||
| Total assets | €9.9M | €16.3M |
| Non-current assets | €3.4M | €5.2M |
| Property, plant & equipment | €1.5M | €1.8M |
| Intangible assets & goodwill | €405.0K | €390.0K |
| Current assets | €6.5M | €11.1M |
| Inventories | €417.0K | — |
| Trade & other receivables | €170.0K | €457.0K |
| Cash & equivalents | €4.2M | €7.0M |
| Total equity | €511.0K | €6.3M |
| Non-current liabilities | €6.6M | €7.0M |
| Lease liabilities (non-current) | €763.0K | €902.0K |
| Current liabilities | €2.8M | €2.9M |
| Lease liabilities (current) | €142.0K | €156.0K |
| Derived metrics | ||
| Free cash flow | -€5.7M | -€16.1M |
| Operating margin | -3149.5% | -8291.2% |
| Net margin | -3131.2% | -8282.4% |
| Return on equity | -1139.7% | -134.0% |
| Cash conversion ratio | 0.98× | 1.80× |
| Capex coverage | — | -16.91× |
| Other reported items | ||
| Adjustments For Amortisation Expense | €103.0K | €509.0K |
| Adjustments For Decrease Increase In Inventories | -€417.0K | €0 |
| Adjustments For Decrease Increase In Trade and Other Receivables | €631.0K | -€1.2M |
| Adjustments For Depreciation Expense | €347.0K | €285.0K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €0 | -€12.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€391.0K | -€5.3M |
| Adjustments For Provisions | €19.0K | €51.0K |
| Adjustments For Sharebased Payments | €36.0K | €935.0K |
| Capital Redemption Reserve | €320.7M | €296.0M |
| Comprehensive Income Attributable To Owners of Parent | -€5.8M | -€8.4M |
| Current Advances | €639.0K | €366.0K |
| Current Contract Liabilities | €46.0K | €231.0K |
| Current Government Grants | -€628.0K | -€2.3M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€4.0K | -€1.0K |
| Equity and Liabilities | €9.9M | €16.3M |
| Finance Income | €153.0K | €30.0K |
| Gains Losses On Exchange Differences On Translation Net of Tax | -€4.0K | -€1.0K |
| Increase Decrease In Cash and Cash Equivalents | -€2.8M | -€5.4M |
| Increase Decrease Through Appropriation of Retained Earnings | — | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €36.0K | €935.0K |
| Increase Decrease Through Transactions With Owners | €36.0K | €10.4M |
| Issue of Equity | — | €9.8M |
| Issued Capital | €8.2M | €32.9M |
| Noncurrent Advances | €4.2M | €4.5M |
| Noncurrent Government Grants | -€1.4M | -€2.8M |
| Noncurrent Provisions For Employee Benefits | €1.0K | €1.0K |
| Other Adjustments For Noncash Items | -€36.0K | -€73.0K |
| Other Comprehensive Income | -€4.0K | €22.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €0 | €23.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€4.0K | -€1.0K |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €0 | €23.0K |
| Other Current Assets | €1.1M | €1.4M |
| Other Current Liabilities | €786.0K | €936.0K |
| Other Expense By Function | €39.0K | €194.0K |
| Other Noncurrent Assets | €95.0K | €137.0K |
| Other Noncurrent Liabilities | €1.6M | €1.6M |
| Other Reserves | €35.8M | €35.7M |
| Proceeds From Government Grants Classified As Financing Activities | €3.1M | €330.0K |
| Proceeds From Issuing Shares | €0 | €9.5M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €15.0K | €1.3M |
| Reduction of Issued Capital | €0 | €0 |
| Research and Development Expense | €3.2M | €4.6M |
| Retained Earnings | -€364.2M | -€358.4M |
| Revenue From Government Grants | €136.0K | €896.0K |
| Selling General and Administrative Expense | €3.2M | €6.0M |
| Share Issue Related Cost | — | €316.0K |
| Trade and Other Current Payables To Trade Suppliers | €1.2M | €1.2M |
Every line item above is a fact tagged in CELYAD ONCOLOGY's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.